Movement Alert｜Illumina Pre-Market Rise 6.34% in Pre-Market Trading, JPMorgan Raises Price Target to 320 USD

Market Focus10-19

On October 19, Illumina rose 6.34% in Pre-Market Trading, trading at 266.16 USD/share, with turnover of 264,600 USD.

The move was supported by a clear event-driven catalyst: JPMorgan raised its price target on Illumina to 320 USD from 230 USD, marking the latest in a series of upward valuation revisions by major brokerages.

Recent supporting context shows TD Cowen lifted its target to 270 USD from 210 USD, while Evercore ISI raised its target to 290 USD from 225 USD. Separately, Illumina recently introduced the BioInsight Platform, a unified software environment integrating genomic analysis tools, AI models, datasets, and DRAGEN v4.6, following the launch of its SpliceAI2 genomic AI model for rare disease research. Illumina is scheduled to report its next quarterly results on October 29, with market expectations for EPS of 1.38.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment